Video
Dr. Whitman on the Partnership Between Atlantic Health System, TGen and Origin
Author(s):
In Partnership With:
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.
On October 4 2018, Atlantic Health System announced a partnership with the Translational Genomics Research Institute and Origin Commercial Ventures to create a new platform to deliver economically accessible immunotherapies and other prominent cancer therapies to the region.
The goal behind the partnership, says Whitman, is to improve the drug pipeline, so that physicians at Atlantic Health have local access to the best therapies and technologies for patients. Community oncologists are very excited by the partnership, explains Whitman, as it enables their patients to stay within the community. Traditionally, a patient who has expended all of their options is referred to a center that is far away. Now, a patient can be referred to a research center on site, enabling much better in-house communication.
